

Mark Garzotto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2656019/publications.pdf>

Version: 2024-02-01

24
papers

294
citations

933447

10
h-index

888059

17
g-index

26
all docs

26
docs citations

26
times ranked

492
citing authors

#	ARTICLE	IF	CITATIONS
1	Editorial Comment. Journal of Urology, 2021, 205, 1688-1688.	0.4	0
2	Sulforaphane Bioavailability and Chemopreventive Activity in Men Presenting for Biopsy of the Prostate Gland: A Randomized Controlled Trial. Nutrition and Cancer, 2020, 72, 74-87.	2.0	41
3	Phytol and its metabolites phytanic and pristanic acids for risk of cancer: current evidence and future directions. European Journal of Cancer Prevention, 2020, 29, 191-200.	1.3	24
4	EDITORIAL COMMENT. Urology, 2020, 145, 157.	1.0	0
5	The estimated prevalence of missed positive lymph nodes based on extent of lymphadenectomy at radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 574.e1-574.e9.	1.6	3
6	Dairy Product Consumption and Prostate Cancer Risk in the United States. Nutrients, 2019, 11, 1615.	4.1	9
7	Optimizing the Sequence of Chemotherapy for Upper Tract Urothelial Carcinoma with Clinically Positive Regional Lymph Nodes. Journal of Urology, 2019, 202, 76-82.	0.4	13
8	Endorectal MR imaging of prostate cancer: Evaluation of tumor capsular contact length as a sign of extracapsular extension. Clinical Imaging, 2018, 50, 280-285.	1.5	7
9	Unconventional Bladder Preservation: Factors Predicting Failure to Receive Definitive Surgery following Chemotherapy for Nonmetastatic Muscle Invasive Bladder Cancer in the National Cancer Database. Journal of Urology, 2018, 200, 535-540.	0.4	4
10	Cyclooxygenase-2 (COX-2) inhibition for prostate cancer chemoprevention: double-blind randomised study of pre-prostatectomy celecoxib or placebo. BJU International, 2017, 119, 709-716.	2.5	24
11	Effects of ω -3 Fatty Acids and Catechins on Fatty Acid Synthase in the Prostate: A Randomized Controlled Trial. Nutrition and Cancer, 2016, 68, 1309-1319.	2.0	21
12	Chemotherapy-Induced Monoamine Oxidase Expression in Prostate Carcinoma Functions as a Cytoprotective Resistance Enzyme and Associates with Clinical Outcomes. PLoS ONE, 2014, 9, e104271.	2.5	30
13	Advances in the Multimodality Management of High-risk Prostate Cancer. Surgical Oncology Clinics of North America, 2013, 22, 375-394.	1.5	1
14	Genomic analysis of prostate cancer.. Journal of Clinical Oncology, 2013, 31, 80-80.	1.6	0
15	SWOG S0421: Phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2012, 30, 4511-4511.	1.6	10
16	The safety of prostate biopsy procedures in the research setting: A 10-year multicenter experience.. Journal of Clinical Oncology, 2012, 30, 87-87.	1.6	0
17	Circulating tumor cell counts (CTC) as prognostic of overall survival (OS) in SWOG S0421-docetaxel with or without atrasentan for metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2012, 30, 10503-10503.	1.6	0
18	Results of telomerase activity measurements from live circulating tumor cells captured on a slot microfilter in a phase III SWOG-coordinated prostate cancer trial (S0421).. Journal of Clinical Oncology, 2012, 30, 4663-4663.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Circulating tumor cell (CTC) counts and CTC telomerase activity (TA) as prognostic markers of overall survival (OS) in SWOG S0421: Docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2012, 30, 1-1.	1.6	21
20	Contemporary Management of High-risk Localized Prostate Cancer. Current Urology Reports, 2010, 11, 159-164.	2.2	11
21	Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer. Cancer, 2010, 116, 1699-1708.	4.1	38
22	Reply to neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer, 2008, 112, 2519-2519.	4.1	0
23	Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 254-259.	1.6	29
24	SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION: A RARE COMPLICATION OF PROSTATE CANCER. Journal of Urology, 2001, 166, 1386-1386.	0.4	8